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Background
Cognitive–behavioural therapy (CBT) is an effective treatment for
Hypochondriacal Disorder, but the long-term effect has not been
examined extensively.
Aims
To investigate the long-term effect of CBT on Hypochondriacal
Disorder using several mental health measures. Follow-up time
was at least 10 years.
Method
A total of 50 patients with a long history of Hypochondriacal
Disorder, diagnosed according to ICD-10, received 16 sessions of
individual CBT and were followed up with an uncontrolled
design. All participants were assessed before and after the
intervention period, and 10 years later. Intention-to-treat mixed-
model repeated-measures analysis were conducted. The study
has been registered at clinicaltrials.gov: NCT00959452.
Results
Patients displayed significant improvements across all out-
comes, including level of health anxiety, somatisation, symp-
toms of anxiety and depression, quality of life, somatisation at
treatment completion. Treatment gains were well maintained 10
years later.
Conclusions
This uncontrolled treatment study suggests that patients treated
with CBT for Hypochondriacal Disorder have significantly
reduced health anxiety 1 year after treatment completion and
the results aremaintained 10 years later. The results indicate that
CBT has a lasting effect, but the lack of a control group and use of
only one therapist, means that care should be taken when gen-
eralising the findings.
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Hypochondriacal Disorder
Hypochondriacal Disorder, or excessive health anxiety, involves
persistent preoccupation with excessive worrying about having or
getting a serious illness.1 The patients focus on physical symptoms,
keep track of all bodily changes and usually misinterpret these as
signs of a serious illness.1,2 The worry and bodily preoccupation per-
sists despite appropriate medical evaluation and reassurance.2,3 The
prevalence of Hypochondriacal Disorder varies greatly across
studies, but has been found to be as high as 5.7% for lifetime
Hypochondriacal Disorder, and 3.4% for current Hypochondriacal
Disorder.2,4,5 The prevalence is substantially higher in primary
care settings than in the general population.2 Of note, in the latest
revision of the DSM (DSM-5), the diagnosis of Hypochondriacal
Disorder or hypochondriasis has been replaced by illness anxiety
disorder.
Untreated Hypochondriacal Disorder has a significant nega-
tive impact on the life of the people affected, with studies
showing higher levels of comorbidity, distress, functional impair-
ment and increased risk of sick leave for patients reporting
Hypochondriacal Disorder.5 Patients with Hypochondriacal
Disorder also have a higher level of healthcare utilisation, up to
78% higher than patients with well-defined medical conditions.6,7
These findings indicate that not only has Hypochondriacal
Disorder a major impact on the lives of those affected, but it
also represents a considerable cost for society.8 This was sup-
ported by the finding in a large Norwegian population study
that Hypochondriacal Disorder was a potent risk factor for
future permanent disability pension.9
Treatment of Hypochondriacal Disorder
Hypochondriacal Disorder was long thought of as an untreatable,
lifelong condition. However, over past decades several studies have
shown beneficial short-term effect of cognitive–behavioural therapy
(CBT) for Hypochondriacal Disorder10,11 but there is still a paucity
of studies examining if treatment gains are maintained over time.
To the best of our knowledge, only one study has followed patients
with Hypochondriacal Disorder beyond 1.5 years after treatment
completion.11–13 In a 5-year follow-up study of 444 UK patients
with Hypochondriacal Disorder, Tyrer et al found CBT to be a
highly effective treatment in reducing levels of health anxiety, as
well as symptoms of anxiety and depression at follow-up.11
Study aim
Based on these considerations, the aim of the current study was to
evaluate both the short- (18 months) and long-term (10 years)
effect of CBT on Hypochondriacal Disorder across different
mental health outcomes. The study has been registered at clinical-
trials.gov with the protocol identifier NCT00959452.
Method
Study design and participants
The study had an uncontrolled, repeated-measures design. Patients
were selected from the Hypochondriac Clinic at Haraldsplass
Deaconal Hospital, in Bergen, Norway, from 1996 to 2001. The
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clinic opened in 1995, only 1 day a week. The clinic receives patients
from all of Norway after referral from general practitioners, medical
specialists or psychologists. Patients from Bergen were offered 16 ses-
sions of CBT whereas patients from other parts of Norway were
offered fewer sessions. Before treatment the patients were diagnosed
using the World Health Organization’s Composite International
Diagnostic Interview (CIDI),14 a structured interview for psychiatric
disorders according to ICD-10.1 All patients fulfilled the diagnostic
criteria for Hypochondriacal Disorder (F45.2)1 as their primary diag-
nosis. Patients were excluded if they had a serious somatic illness, had
psychosis or were diagnosed with alcohol and/or substance misuse.
Baseline data were collected at the start of therapy and all patients
received 16 sessions of individual CBT, each session lasting 45–50
min, given over a period of 8–12 months. Patients were included
in the long-term follow-up study at the scheduled control 1 year
after the last session and because of the relatively long treatment
and follow-up period only patients from the Bergen area were
included in the study. The first 50 patients who fulfilled the diagnos-
tic criteria for Hypochondriacal Disorder, had not developed any
serious somatic disease during the treatment period and agreed to
participate in the long-term follow-up were included. Two patients
withdrew during the follow-up period and their data were excluded
from the analysis. No patients died during the study period.
One therapist (I.W.) treated all the patients in this study. I.W. was
educated in CBT ad modum Aaron Beck, and he is a certified super-
visor of CBT in TheNorwegianAssociation ofCognitive Therapy and
a member of Academy of Cognitive Therapy. The therapist did not
focus on the physical symptoms presented, but rather examined
and questioned how the patients interpreted their symptoms.
Research has found that reassurance has a negative effect on
Hypochondriacal Disorder,15 which is supported by the fact that
the patients in this study had the condition for more than a decade,
in spite of numerous consultations with doctors, multiple tests and
medical examinations.
The patients in this study differed in many ways, but the themes
focused on in therapy were the same for all of them. The patients’
metacognitions on rumination and worrying were always examined.
It became clear that the patients tried to control factors that are in
principle uncontrollable,16 such as death and the future. The patients
were told that they cannot choose whether they have or will get a
serious somatic disease or not, but they can choose what to believe,
until further notice. Even though they had to make this decision
with some doubt, they were asked not to make a doubtful decision.
Thus, the patients were challenged to accept uncertainty as a given
fact of life, and spend their life on living rather than on not dying.
If the patient adopted new attitudes toward subjective symptoms,
worrying, death and uncertainty, their homework assignment was
to behave as if they meant it, in other words start doing things they
had avoided before.
All patients completed a range of self-reported questionnaires at
three assessment points: before (pre-CBT) and after (post-CBT)
receiving the treatment, and at the 10-year follow-up. The pre-
and post-CBT forms were completed at the hospital, whereas the
10-year follow-up assessment was by postal mail and telephone
interview. In addition to data collected during the intervention
study, we also used data on quality of life from a national represen-
tative sample of 3500 Norwegians. More details on this norm study
has been published elsewhere.17
Ethics and consent
The study protocol was cleared by the Regional Committee for
Medical Research Ethics of Western Norway and approved by the
Norwegian Data Inspectorate. Informed consent in writing was
obtained from all participants included in this study. All patients
could withdraw from the study at any time, without giving any
reasons for why they might want to withdraw from the study.
This would not affect their further therapy.
Instruments and measures
Whiteley Index, 14-item and 6-item versions
The Whiteley Index, a 14-item Likert questionnaire, is a self-report
measure to screen for Hypochondriacal Disorder. It was first used by
Pilowsky in 1969, and has been widely used for the screening of
Hypochondriacal Disorder.18 The Whiteley Index has been found to
have good psychometric properties, although the factor structure has
been questioned.19 TheWhiteley Index consists of 14 items that origin-
ally were used dichotomously (true/false). A 5-point Likert scale version
was later established,with the responseoptions labelled as follows: 1, ‘not
at all’; 2, ‘to someextent’; 3, ‘moderately’; 4, ‘to a considerable extent’; and
5, ‘to a great extent’. The dichotomous version of the Whiteley Index is
still the versionmostly used, although the Likert scale version is claimed
to differentiate better than the dichotomous version.20 The version
employed in the current study includes the Likert scaled response
options. In a recent Norwegian study a shorter version of the Whiteley
Index, including only six items, was found to have better psychometric
properties than the original 14-item version.19 In the current study,
both the 6-item and the original 14-item Whiteley Index were used.
Cronbach’s alphas were 0.93 at all three assessment points.
Next-of-kin questionnaire
For the purposes of the present study, we adapted the Whiteley
Index to be filled out by the participants’ partner or a close relative.
This next-of-kin-questionnaire is a Likert-scale questionnaire, with
a response scale of 1–5, where 1 equals ‘not at all’, and 5 is ‘to a great
extent’, similarly to theWhiteley Index. The questionnaire estimates
the patient’s health complaints from a next-of-kin perspective. The
Cronbach’s alphas in the current study were 0.81 pre-CBT, 0.89
post-CBT and 0.93 for the 10-year follow-up.
The Short Form Health Survey
The Short Form 36 Health Survey (SF-36) is one of the most used
generic questionnaires for measuring quality of life and is often
referred to as the ‘gold standard’ within research on health-related
quality of life. The SF-36 includes 36 questions that are summed
into eight multi-item subscales. The raw scores are transformed
into a scale of 1–100, where low scores indicate lower quality of
life, and high scores indicate higher quality of life, and the lower
the score, the more disability.21 The Norwegian translation of the
SF-36 has shown good reliability and validity. The norms used in
this paper were weighted to match the gender and age distribution
in the range of patients with Hypochondriacal Disorder.17
Visual analogue scales
Three visual analogue scales (VAS) were used to assess
Hypochondriacal Disorder. Each of the three scales comprising a
millimetre scale from 0 to 100, where 0 represents optimal health/
no Hypochondriacal Disorder, and 100 represents bad/severely
bad health/Hypochondriacal Disorder. The three VAS included:
(a) the tendency ofHypochondriacalDisorder over the past 2weeks;
(b) the tendency to check their body over the past 2 weeks; and
(c) the tendency to think of certain symptoms and bodily changes
over the past 2 weeks.22
The Beck Depression Inventory
The Beck Depression Inventory (BDI) is one of the most widely
used instruments assessing symptoms of depression. The BDI
Veddegjærde et al
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includes 21 items along a 4-point scale (range 0–3) on a 3-day time
axis.23 Higher scores indicate more severe depressive symptoms,
with cut-offs ranging from ‘minimal depression’, ‘mild depression’,
‘moderate depression’ and ‘severe depression’. The Cronbach’s
alphas in the current study were 0.84 pre-CBT, 0.89 post-CBT
and 0.92 for the 10-year follow-up.
The State–Trait Anxiety Inventory
The State–Trait Anxiety Inventory (STAI) is a commonly used
measure of trait and state anxiety, based on a 4-point Likert scale.
It consists of 40 questions on a self-report basis.24 Higher scores
are positively correlated with higher levels of anxiety. It can be
used in clinical settings to aid diagnosis of anxiety and to distinguish
it from depressive syndromes. Each of the two subscales (state and
trait anxiety) consists of 20 questions, rated on a 4-point scale (range
1–4). The Cronbach’s alphas in the current study were 0.77 pre-
CBT, 0.68 post-CBT and 0.66 for the 10-year follow-up, and the cor-
responding values for the state subscale were 0.64 pre-CBT, 0.66
post-CBT and 0.58 for the 10-year follow-up.
The Somatosensory Amplification Scale
The Somatosensory Amplification Scale (SSAS) is a 10-item ques-
tionnaire assessing how much patients are preoccupied by various
symptoms and sensations, including somatic sensations.25 These
symptoms are mostly not pathological symptoms of serious dis-
eases. The response options range from 1 (‘not at all’) to 5
(‘extremely’). The main difference between the Whiteley Index
and the SSAS is that the Whiteley Index focuses on attitudes, con-
cerns, beliefs and fears about health and disease whereas the SSAS
focuses on discomfort associated with bodily sensations.25 The
Cronbach’s alphas in the current study were 0.70 pre-CBT, 0.79
for post-CBT and 0.82 for the 10-year follow-up.
The Giessen Subjective Health Complaints
The Giessen Subjective Health Complaints (GSHC) scale is a
symptom scale of bodily symptoms and discomfort.26 It includes
60 items each rated on a 5-point Likert scale from 0, not at all, to
4, very much. The time span of the scale is 1 week. Total score
was computed for the GSHC. The Cronbach’s alphas in the
current study were 0.91 pre-CBT, 0.86 post-CBT and 0.94 for the
10-year follow-up.
Ten-year follow-up telephone interview
In addition to the postal questionnaires at the 10-year follow-up, a
brief telephone interview was conducted with all the patients. The
following questions were asked:
(a) Do you still consider yourself to suffer from Hypochondriacal
Disorder? (Yes/No);
(b) Do you use as much time now as you used to, to check for
symptoms and scan your body? (Yes/No);
(c) Are you currently using any antidepressants? (Yes/No); and
(d) Have you received any type of psychotherapy after the end of
CBT? (yes/no/type of therapy).
Information on age, gender, relationship status, use of medi-
cines, education and work status was also collected from the
patients.
Statistics
Linear mixed models for repeated-measures analysis were imple-
mented using the intention-to-treat principle, so that all patients
with baseline data were included in the analysis. Mixed-model ana-
lysis (MAR) use data from all informants irrespective of the number
of assessment points. No covariates were entered into the model.
There are no conclusive tests to prove the assumption of MAR, it
is, however, generally considered to be a more realistic assumption
as compared with missing completely at random or missing not at
random. Standardised mean differences were calculated as the mean
difference between two assessment points divided by the baseline
s.d., in line with the recommendations of Carlson & Schmidt and
Morris.27,28 For the SF-36, independent samples t-tests were used
to compare patients with Hypochondriacal Disorder with norm
scores based on mean, s.d. and sample size.17 The normality of
the data was examined using skewness and kurtosis, and all continu-
ous measures (except Whiteley Index 14-item total) were well
within the recommended ranges (+/− 2). All data analyses were
conducted using the IBM SPSS Statistics, version 23.
Results
Participant characteristics
The mean age at baseline inclusion was 35 years (s.d. = 8.8, range
21–55), and the participants included a majority of women (n =
41, 82%). In total, 32 (64%) of the participants were employed
and 41 (82%) were married or living with a partner. On average,
the participants had been diagnosed with Hypochondriacal
Disorder for 11.3 years (s.d. = 8.3) at the time of inclusion. The
most common disease the patients worried about was cancer, fol-
lowed by heart-related diseases and neurological diseases, such as
multiple sclerosis or amyotrophic lateral sclerosis. There were 34
(68%) participants who also had lifetime comorbid mental disor-
ders, the most frequent being depression in 17 of the participants
Table 1 Baseline descriptive statistics for the included outcome
measures
Median IQR Skewness Kurtosis
Health anxiety
Whiteley 6-item, total 21.5 4.3 −1.0 2.3
Whiteley 14-item, total 49.0 8.5 −1.4 3.0
Whiteley 14-item, next of kin
version
31.0 10.9 −0.6 −0.5
VAS, tendency to think of
(bodily) symptom
7.2 2.9 −0.8 0.8
VAS, tendency of health
anxiety
6.6 3.9 −0.7 −0.2
VAS, tendency to check for
bodily symptoms
6.5 4.3 −0.5 −0.9
Quality of life
SF-36, physical role 50.0 75.0 −0.1 −1.5
SF-36, emotional role 33.3 66.7 0.7 −0.6
SF-36, physical problems 92.5 15.0 −1.1 0.0
SF-36, social functioning 61.1 33.3 −0.2 −0.7
SF-36, mental health 54.0 20.0 −0.2 −0.5
SF-36, energy, vitality 35.0 28.8 0.6 0.0
SF-36, pain 51.0 31.0 0.2 −0.5
SF-36, general health
perception




26.5 8.3 −0.1 −0.6
Giessen Subjective Health
Complaints, total




50.0 15.3 −0.1 −1.0
State–Trait Anxiety Inventory,
State
48.0 12.3 −0.8 0.3
Beck Depression Inventory 20.0 12.3 −0.1 −0.6
IQR, interquartile range; VAS, visual analogue scale; SF-36, Short Form 36 Health Survey.
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(34%: F32) and generalised anxiety (F41.1) in 14 (28%) of the par-
ticipants. In most cases, the depression was considered secondary to
the patient’s Hypochondriacal Disorder, and Hypochondriacal
Disorder was always the main diagnosis. In terms of medication
use, 4 (8%) of the patients were taking antidepressants at inclusion.
Table 1 details the descriptive statistics (median, interquartile range,
skewness and kurtosis).
Symptoms of hypochondriasis
There were significant reductions in levels of Hypochondriacal
Disorder scores from pre- to post-CBT, with large effect sizes
ranging from a standardised mean difference (SMD) of 0.45 to
2.06. Analyses of the 10-year follow-up-data showed that the treat-
ment gains were well maintained 10 years later, with no statistically
significant changes from post-CBT to 10-year follow-up (see Table 2
for details).
Quality of life
There were significant improvements across all eight SF-36 sub-
scales from pre- to post-treatment, with effect sizes ranging from
a SMD of 0.55 to 1.65. As with the Hypochondriacal Disorder out-
comes, the treatment gains were well maintained at the 10-year
follow-up (no significant changes from post-treatment to 10-year
follow-up). As displayed in Fig. 1, compared with national norms,
patients reported significantly lower levels of quality of life across
all eight SF-36 subscales at pre-treatment. At post-treatment, six
of the subscales no longer differed from the population norms,
whereas the subscales ‘physical functioning’ and ‘role limitation
due to physical problems’ were still below the norms. The same
pattern was observed at 10-year follow-up.
Somatisation
Both the SSAS and GSHC total score showed significantly reduced
levels of somatic complaints from pre- to post-treatment (effect
sizes ranging from a SMD of 0.89 to 1.23). The 10-year follow-up
analyses show that these treatment benefits were maintained 10
years later, with effect sizes ranging from a SMD of 0.92 to 1.34.
Mental health problems
The BDI showed a significant reduction in depression symptoms
from pre- to post-treatment, with an effect size of SMD = 1.11,
and the treatment gains were maintained at the 10-year follow-up
assessment. (SMD = 0.92).
In terms of clinical cut-off, 9 (18%) and 10 (20%) participants
fulfilled the criteria for mild depression (BDI total score <7) at
post- treatment and 10-year follow-up, respectively, compared to
14 (28%) pre-treatment (P < 0.001). For moderate depression, 2
(4%) and 1 (2%) fulfilled the criteria at post- treatment and 10-
year follow-up, respectively, compared with 15 (30%) pre-treatment
(P < 0.001).



















Whiteley 6-item, total 19.6 (4.9) 13.9 (4.4) 13.5 (4.5) 1.19 0.89 to 1.60 1.25 0.94 to 1.65 <0.001 <0.001 0.214
Whiteley 14-item, total 46.1 (10.9 34.1 (10.4) 33.5 (10.9) 1.11 0.77 to 1.47 1.16 0.81 to 1.51 <0.001 <0.001 0.190
Whiteley 14-tiem, next
of kin version
30.4 (6.6) 23.2 (6.0) 19.9 (8.9) 1.09 0.63 to 1.48 1.60 0.93 to 2.15 <0.001 <0.001 0.031
VAS, tendency to think
of bodily symptoms
6.9 (2.2) 2.5 (2.4) 3.0 (3.1) 2.06 1.38 to 2.54 1.81 1.15 to 2.35 <0.001 <0.001 0.231
VAS, tendency of health
anxiety
6.3 (2.2) 1.9 (1.9) 1.9 (1.9) 2.01 1.50 to 2.53 2.01 1.18 to 2.29 <0.001 <0.001 0.175
VAS, tendency to check
for bodily symptoms
6.2 (2.7) 1.9 (2.0) 3.4 (6.1) 1.58 1.17 to 2.06 1.02 0.30 to 1.78 <0.001 0.005 0.119
Quality of life
SF-36, physical role 86.5 (15.9) 93.7 (9.6) 91.0 (14.4) −0.45 −0.73 to −0.21 −0.28 −0.56 to −0.05 <0.001 0.034 0.150
SF-36, emotional role 34.5 (35.0) 85.3 (26.4) 75.8 (39.0) −1.45 −1.88 to −0.70 −1.18 −1.63 to −0.70 <0.001 <0.001 0.122
SF-36, physical
problems
53.8 (38.6) 88.4 (24.7) 82.0 (34.2) −0.90 −1.26 to −0.56 −0.73 −1.12 to −0.35 |<0.001 <0.001 0.262
SF-36, social functioning 55.5 (22.8) 76.5 (18.6) 73.2 (23.5) −0.92 −1.24 to −0.59 −0.77 −1.13 to −0.40 <0.001 <0.001 0.306
SF-36, mental health 52.7 (16.0) 75.9 (14.9) 73.6 (17.5) −1.46 −1.93 to −1.07 −1.31 −1.77 to −0.92 <0.001 <0.001 0.398
SF-36, energy, vitality 36.7 (21.0) 60.3 (15.6) 65.0 (58.8) −1.12 −1.47 to −0.76 −1.35 −1.52 to −0.58 <0.001 0.002 0.578
SF-36, pain 53.9 (23.1) 73.8 (21.9) 75.4 (24.3) −0.86 −1.22 to −0.50 −0.93 −1.31 to −0.51 <0.001 <0.001 0.695
SF-36, general health
perception








109.5 (24.2) 91.4 (22.3) 88.8 (24.1) 0.33 0.44 to 1.11 0.43 0.51 to 1.21 <0.001 <0.001 0.488
Mental health problems
STAI-Trait 48.8 (6.9) 43.6 (7.2) 42.8 (9.3) 0.77 0.42 to 1.11 0.88 0.46 to 1.31 <0.001 <0.001 0.584
STAI-State 45.5 (10.2) 36.3 (13.09 33.4 (9.6) 0.90 0.47 to 1.34 1.18 0.75 to 1.54 <0.001 <0.001 0.131
Beck Depression
Inventory
15.0 (8.3) 6.7 (6.5) 7.2 (8.7) 1.00 0.65 to 1.36 0.94 0.56 to 1.36 <0.001 <0.001 0.727
SF-36, Short Form 36 Health Survey; STAI, State–Trait Anxiety Inventory.
a. The 95% CI for standardised mean difference were calculated in Mplus version 8.
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There were also significant improvements in symptoms of
anxiety (STAI-Trait and STAI-State) from pre- to post-treatment,
with effect sizes of SMD = 0.69 and SMD = 0.79, respectively. As
with the other outcomes, these treatment gains were maintained
at 10-year follow-up, with effect sizes of SMD = 0.96 (STAI-Trait)
and SMD = 1.21 (STAI-State).
Ten-year follow-up telephone interview
At 10-year follow-up, 29 (58%) of the patients reported that they no
longer had Hypochondriacal Disorder; 12 (24%) reported that they
still spent a lot of time checking their body for symptoms; and 10
(20%) reported using antidepressants. A total of 34 (68%) of the parti-
cipants reported not receiving any type of therapy since treatment
completion.
Discussion
The aim of this small and uncontrolled treatment study was to
investigate the short- and long-term effect of CBT on
Hypochondriacal Disorder. In short, treated patients (n = 50) dis-
played significant improvements across all outcome measures,
and treatment gains were well maintained even 10 years after treat-
ment completion, suggesting that CBTmay have lasting benefits for
this patient group. Some important study limitations mean that care
should be taken when generalising the results.
Several controlled clinical studies have found that CBT has a
positive short-term effect in patients with Hypochondriacal
Disorder. In a six-session individual CBT intervention, Barsky &
Ahern found that the positive effect on Hypochondriacal Disorder
was maintained at both 6- and 12-month follow-up.13 Greeven
et al found sustained positive effect of CBT in an 18-month follow-
up.29 In this long-term follow-up study we found that the short-
term positive effect of 16 sessions of CBT at the 1-year follow-up
were maintained after 10 years. Our findings are in line with the con-
clusion of a recent report from the National Institute of Health
Research (NIHR) in the UK that included a 5-year follow-up of
patients with Hypochondriacal Disorder receiving CBT.11 As the
NIHR report showed, the treatment gains were evident across a
range of mental and physical health domains, and not just limited
to symptoms of Hypochondriacal Disorder. As a result of the lack
of a control group and the long time-range between inclusion and
end of our study we cannot conclude that the maintenance of the
positive clinical status is attributed to CBT alone, but given the fact
that the patients had a long history of Hypochondriacal Disorder,
with a mean time of 11.3 years before receiving CBT, it is, in our
opinion, a strong indication that the long-term treatment effect is
positive. However, we cannot conclude that CBT is the only effective
treatment since the study did not include other therapies.
The treatment gains displayed across all self-report question-
naires used in the current study was corroborated by the findings
from the telephone interview carried out at the 10-year follow-up
assessment, where as many as 58% of the patients no longer consid-
ered themselves as having Hypochondriacal Disorder. Several
studies have shown that patients with Hypochondriacal Disorder
or excessive health anxiety are high utilisers of healthcare
resources.2,6,30–32 As the condition in many patients with
Hypochondriacal Disorder is left undetected and untreated,2,7
there may therefore be substantial socioeconomic benefits in
improved diagnostic practices and treatment availability for this
patient group. However, the previously mentioned NIHR study
found it difficult to show economic benefits for this in terms of
quality-adjusted life-years,11 but the current study shows a signifi-




































Pre-treatment Post-treatment 10-year follow-up
Fig. 1 Health-related quality of life (Short Form 36 Health Survey) at the three assessment points in patients with hypochondriasis treated with
cognitive–behavioural therapy, compared with Norwegian norms.
PF, physical functioning; RP, role functioning –physical role limitations due to physical health; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role
functioning – emotional role limitations due to emotional problems; MH, mental health.
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Methodological limitations
Some important methodological limitations should be noted. Most
importantly, the current study was not a randomised controlled
trial. The lack of a control group means that we cannot disregard
the possibility that the observed treatment effects may partly be
because of time passing or regression to the mean. As such, care
should be taking when interpreting the results, and future studies
should address this by also including a control group, preferably
with an active comparison treatment group. By comparing our find-
ings with trait existing national norms of the SF-36, the obvious
weakness of not having a control group was somewhat addressed.
Furthermore, the statistical power of the current study is limited
by a relatively small sample size, and larger studies will allow for
more detailed analysis of potential moderators in the future. Also,
some of the Cronbach’s alphas were less than optimal, and the
results should be interpreted with this in mind. Moreover, it
should be mentioned that only one therapist (I.W.) was involved
in treatment. Although this may limit the generalizability of the
study, one could argue that continuity was maintained in treatment.
Finally, all instrument measures in the current study were based on
self-report, and no clinician-verified information was included.
However, the next-of-kin version of the Whiteley Index instrument
displayed similar treatment gains, indicating the existence of treat-
ment gains across informants.
Strengths
The current study has the longest follow-up in any
Hypochondriacal Disorder treatment study, which is a significant
study strength. Also, the drop-out rate across all three assessment
points (from pre-treatment to 10-year follow-up) was only 14%,
which is much lower than previous studies of treatment for
Hypochondriacal Disorder.13
Implications
In conclusion, this study demonstrates that patients treated with
CBT for Hypochondriacal Disorder have significantly reduced
health anxiety 1 year after treatment completion and the results
are maintained 10 years later. As a result of the long follow-up
period and the lack of a control group, the positive results cannot
be attributed to the therapy alone and because one therapist
treated all the patients this limits the generalizability of the findings.
The results are, however, an indication that CBT has a long-lasting
effect on Hypochondriacal Disorder.
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